share_log

Mangoceuticals | CORRESP: CORRESP

SEC ·  May 8 01:03
Summary by Futu AI
Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1. The initial filing was made on April 23, 2024, and has since been amended. The company, headquartered in Dallas, Texas, seeks to have the registration become effective at 4:30 p.m. EDT on May 9, 2024. This request was communicated through a letter addressed to the SEC, specifically to Juan Grana of the Division of Corporation Finance, and signed by Jacob D. Cohen, Chairman and CEO of Mangoceuticals.
Mangoceuticals, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1. The initial filing was made on April 23, 2024, and has since been amended. The company, headquartered in Dallas, Texas, seeks to have the registration become effective at 4:30 p.m. EDT on May 9, 2024. This request was communicated through a letter addressed to the SEC, specifically to Juan Grana of the Division of Corporation Finance, and signed by Jacob D. Cohen, Chairman and CEO of Mangoceuticals.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.